ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Vitamin D Deficiency Linked to Neurological Diseases; Also Raises Risk of Asthma Attacks, and More

7 Best Foods You Can Eat

Study: Doubling saturated fat in the diet does not increase saturated fat in blood

The Gut Microbiome and the Brain

Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed

CoQ10 supplementation reduces statin-related muscle pain in randomized trial

Controlling obesity with potato extract

Plant used in traditional Chinese medicine may treat metabolic diseases and obesity

Natural Gut Viruses Join Bacterial “Cousins” in Maintaining Health and Fighting Infections

Proton pump inhibitors decrease diversity in gut microbiome, increase risk for complications

 
Print Page
Email Article

Profile of adverse events with duloxetine [Cymbalta] treatment: a pooled analysis of placebo-controlled studies – Source: Drug Safety, May 1, 2010

  [ 58 votes ]   [ Discuss This Article ]
By S Brunton, et al. • www.ProHealth.com • April 22, 2010


The serotonin and noradrenaline (norepinephrine) reuptake inhibitor duloxetine [brand names Cymbalta, Yentreve] has been approved in the US and elsewhere for a number of indications, including psychiatric illnesses and chronic pain conditions.

Because the patient populations are diverse within these approved indications, and duloxetine is not yet approved for treatment of other conditions, we wanted to determine if adverse event profiles would differ among patients being treated for these various conditions.

To provide detailed information on the adverse events associated with duloxetine and to identify differences in the adverse event profile between treatment indications and patient demographic subgroups.

Data were analyzed from all placebo-controlled trials of duloxetine completed as of December 2008. The 52 studies included 17,822 patients (duloxetine n = 10 326; placebo n = 7496) with major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, osteoarthritis knee pain (OAKP), chronic lower back pain and lower urinary tract disorders.

The main outcome measures were rates of treatment-emergent adverse events (TEAEs) and adverse events reported as the reason for discontinuation.

• The overall TEAE rate was 57.2% for placebo-treated patients and 72.4% for duloxetine-treated patients (p = 0.001 or less).

• Patients with osteoarthritis knee pain had the lowest TEAE rate (placebo 36.7% vs duloxetine 50.2% (p = 0.01 or less),

• While patients with fibromyalgia had the highest rate (placebo 80.0% vs duloxetine 89.0% (p = 0.001 or less).

The most common TEAE for all indications was nausea (placebo 7.2% vs duloxetine 23.4% (p = 0.001 or less), which was predominantly mild to moderate in severity. No statistically significant treatment-by-subgroup interactions for age were found between placebo and duloxetine treatment for the most common TEAEs.

The rates of duloxetine-associated dry mouth and fatigue were greater in women than in men (13.1% vs 10.4%, interaction p = 0.004; and 9.4% vs 7.6%, interaction p = 0.03, respectively).

Duloxetine-associated dry mouth incidence was higher in Caucasians than non-Caucasians (13.2%, 11.0%, interaction p = 0.04).

Duloxetine treatment is associated with significantly higher rates of common TEAEs versus placebo, regardless of indication or demographic subgroup.

Differences across indications are likely to be attributable to the underlying condition rather than duloxetine, as suggested by the similar trends observed in placebo- and duloxetine-treated patients.

Source: Drug Safety, May 2010;33(5):393-407. PMID: 20397739, by Brunton S, Wang F, Edwards SB, Crucitti AS, Ossanna MJ, Walker DJ, Robinson MJ. Faculty Development, Cabarrus Family Medicine Residency, Concord, North Carolina, USA.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Live Longer: Groundbreaking Research on Omega-3s Live Longer: Groundbreaking Research on Omega-3s
A Breakthrough for Mitochondrial Dysfunction A Breakthrough for Mitochondrial Dysfunction
Natural Support for Mood, Sleep and Mental Focus? L-theanine Natural Support for Mood, Sleep and Mental Focus? L-theanine
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing